Kymriah (Tisagenlecleucel) of Novartis Korea, a "one-shot treatment" with an ultra-high cost of 500 million won per dose, passed the Cancer Drugs Benefit Appraisal Committee.

At the Cancer Drugs Benefit Appraisal Committee held last month, the gap between health authorities and pharmaceutical companies was barely narrowed at the second Cancer Drugs Benefit Appraisal Committee.

The HIRA released the "7th Cancer Drugs Benefit Appraisal Committee Deliberation Results in 2021" on the afternoon of the 13th. The HIRA, like the Cancer Drugs Benefit Appraisal Committee and the Cancer Drugs Benefit Appraisal Committee this month, decided to disclose the results of the deliberation to the media aft